BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model

According to the company's explanation, bacteriophages have been mainly used for R&D on bacterial infectious diseases, but recently the scope of applic...

April 04, 2023 | News

Ablaze Pharmaceuticals to Develop GPC3 Targeted Therapy for Liver Cancer in China

The proprietary GPC3 targeting peptide is being licensed from RayzeBio pursuant to an existing license agreement. Upon in-license of product candidates by ...

March 31, 2023 | News

ImmVira's MVR-C5252 for Malignant Glioma Approved for Clinical Trial in China

In July 2022, the Company entered into a cooperative agreement with China Resource Biopharma ("CRBio") to jointly develop MVR-C5252 in the Greate...

March 30, 2023 | Regulatory

Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063

Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small mole...

March 30, 2023 | Regulatory

Kintor Pharma Completes Enrollment for KX-826 Phase III Trial for Male Androgenetic Alopecia in China

The Phase III clinical trial is a randomized, double-blind, placebo-controlled, multi-regional study designed to evaluate the efficacy and safety of 5mg (0...

March 29, 2023 | News

Antengene Doses First Patient with ATG-022 for Advanced Solid Tumors in Australia

Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antig...

March 29, 2023 | News

YS Biopharma's PIKA COVID-19 Vaccine Shows Better Antibody Response Than Inactivated Vaccine in Phase II Study

The trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inactivated COVID-19 vaccine, measured by GMT of neutralizing a...

March 28, 2023 | News

Phase 1 trial of OLX72021of Treatment of Androgenic Alopecia has been approved for initiation in Australia

OliX will evaluate the safety and tolerability of OLX72021 in Phase 1 clinical trial Excellent hair growth effect is observed when used as external solu...

March 27, 2023 | News

Enveric Biosciences Selects Australian CRO, Avance Clinical

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of nove...

March 27, 2023 | News

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Dr...

March 23, 2023 | News

Cancer Research UK Funded Trial Finds that Chemotherapy Before Surgery Cuts the Risk of Colon Cancer from Returning

Led by the University of Birmingham and the University of Leeds, the Cancer Research UK-funded FOxTROT trial found that giving colon cancer patients c...

March 22, 2023 | News

Jacobio Collaborates to Evaluate JAB-BX102 with KEYTRUDA® for Cancer Patients.

Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combinatio...

March 22, 2023 | News

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

ADC drugs have the advantages of highly specific targeting of antibody and anti cancer activity of cytotoxin. ADC shave developed rapidly as tumor therapeu...

March 16, 2023 | News

FDA approves Abbisko Therapeutics' Pimicotinib for Phase III clinical trial

This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib （ABSK021）was granted BTD by FDA and CDE, discovered a...

March 16, 2023 | News

Stay Connected